The presence of any of 59 possible EGFR mutations in exons 18-21 (including the T790M mutation in exon 20) is identified by real-time polymerase chain reaction.

Cytogenetic abnormalities commonly associated with multiple myeloma (MM) are detected by fluorescence in situ hybridization (FISH). Probes for CKS1B-CDKN2C (1p32.3/1q21.3), 5q (5q-/-5/+5), 13q (13q-/-13), TP53 (17p13.1), IGH/FGFR3 t(4;14), IGH/CCND1 t(11;14), IGH/MAF t(14;16), IGH/MAFB t(14;20) are included in the Myeloma FISH Profile.

Cytogenetic abnormalities commonly associated with high-grade B-cell non-Hodgkin lymphomas (NHL) are detected by fluorescence in situ hybridization (FISH). Probes for BCL6 (3q27.3), IRF4-DUSP22 (6p25.3), MYC (8q24.21), IGH/BCL2 t(14;18)) are included in the B-NHL High-Grade FISH Profile (Enriched). B-cells are enriched from patient’s specimen using immunomagnetic enrichment technology with CD19/CD20 antibodies.

Histologic examination of prostate tissue. Surgical pathology level 4 (per individually identified specimen site), with microscopic interpretation and report.

A tech-only 25-marker screening profile for myeloma. An evaluation of specimen adequacy and cellular integrity will also be performed. Markers include cKappa, cLambda, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD13, CD14, CD16, CD19, CD20, CD34, CD38, CD45, CD56, CD57, CD117, CD138, HLADR, Kappa, and Lambda.

The Mature B-Cell/Hairy Cell Panel by flow cytometry aids in the subtyping of mature B-cell neoplasms. Available as an add-on in conjunction with, or after, a Diagnostic/Prognostic Profile result has been reported by Genoptix or client. Markers tested by flow cytometry include CD5, CD11c, CD19, CD23, CD25, CD45, CD103 and FMC7.

A tech-only 24-marker screening profile for bone marrow specimens. An evaluation of specimen adequacy and cellular integrity will also be performed. Markers include CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD13, CD14, CD16, CD19, CD20, CD33, CD34, CD38, CD45, CD56, CD57, CD64, CD117, HLADR, Kappa and Lambda.

A flow cytometry profile, with additional rational marker selection for phenotyping (up to 35 total antibodies). An evaluation of specimen adequacy and cellular integrity will also be performed.

Available in conjunction with, or after, a Diagnostic/Prognostic Profile result has been reported by Genoptix or client. Markers tested by flow cytometry include cLambda, cKappa, CD5, CD10, CD19, CD20, CD45 and CD103.

The Sezary Syndrome Panel by flow cytometry aids in the diagnosis of Sezary syndrome and mycosis fungoides. Available in conjunction with, or after, a Diagnostic/Prognostic Profile result has been reported by Genoptix or client. Markers tested by flow cytometry include CD3, CD4, CD7, CD8, CD26 and
CD45